The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections
Abstract
Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci, and enterococci. The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis. A novel and practical asymmetric synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones has been developed and is employed for the synthesis of U-100592 and U-100766. This involves the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
McConnell, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70621-1 · Cited by 541
Multiple-Antibiotic-Resistant Pathogenic Bacteria -- A Report on the Rockefeller University Workshop
Tomasz, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301725 · Cited by 418
Blumberg, H. M., Rimland, D., Carroll, D. J., Terry, & Wachsmuth, I. K. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.6.1279 · Cited by 319
Hospital-acquired infections: diseases with increasingly limited therapies.
Swartz, M. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2420 · Cited by 232
Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis
Eustice, D. C., Feldman, P., Zajac, I., & Slee, A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.8.1218 · Cited by 118
Multidrug-Resistant Enterococcus faecium
Spera, R. V., & Farber, B. F. (1994) · Drugs · doi:10.2165/00003495-199448050-00003 · Cited by 90
Ashtekar, D. R., Costa-Periera, R., Shrinivasan, T., Iyyer, R., Vishvanathan, N., & RITTEL, W. (1991) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(91)90002-w · Cited by 74
Cited by
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Genin, M. J., Allwine, D. A., Anderson, D. J., Barbachyn, M. R., Emmert, D. E., Garmon, S. A., Graber, D. R., Grega, K. C., Hester, J. B., Hutchinson, D. K., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990373e · Cited by 729
Self-citationHighly Efficient and Mild Copper‐Catalyzed N‐ and C‐Arylations with Aryl Bromides and Iodides
Cristau, H., Cellier, P. P., Spindler, J., & Taillefer, M. (2004) · Chemistry – A European Journal · doi:10.1002/chem.200400582 · Cited by 586
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
Oxazolidinone Structure–Activity Relationships Leading to Linezolid
Barbachyn, M. R., & Ford, C. W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200528 · Cited by 553
Self-citationStevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Targeting Antibiotic Resistance
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506818 · Cited by 487
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/318486 · Cited by 440
Roehrig, S., Straub, A., Pohlmann, J., Lampe, T., Pernerstorfer, J., Schlemmer, K.-H., Reinemer, P., & Perzborn, E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050101d · Cited by 436
Oxazolidinones: activity, mode of action, and mechanism of resistance
Bozdogan, B., & Appelbaum, P. C. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.003 · Cited by 403
Important fluorinated drugs in experimental and clinical use
Ismail, F. M. D. (2002) · Journal of Fluorine Chemistry · doi:10.1016/s0022-1139(02)00201-4 · Cited by 398
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
An overview of benzo [b] thiophene-based medicinal chemistry
Keri, R. S., Chand, K., Budagumpi, S., Balappa Somappa, S., Patil, S. A., & Nagaraja, B. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.038 · Cited by 356
New approaches for treating staphylococcal biofilm infections
Kiedrowski, M. R., & Horswill, A. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06281.x · Cited by 288
Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones
McKee, E. E., Ferguson, M., Bentley, A. T., & Marks, T. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-05 · Cited by 270
Lin, A. H., Murray, R. W., Vidmar, T. J., & Marotti, K. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2127 · Cited by 261
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Self-citationDrugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Metadata
- Authors
- Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., & Zurenko, G. E.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1996-01-01
- Volume
- 39
- Issue
- 3
- Pages
- 673-679
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2168635615
- Cited by
- 582
- References
- 8
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.